Compare · APP vs TEM
APP vs TEM
Side-by-side comparison of Applovin Corporation (APP) and Tempus AI Inc. (TEM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APP and TEM operate in Computer Software: Programming Data Processing (Technology), so they compete in similar markets.
- APP is the larger of the two at $187.19B, about 22.5x TEM ($8.34B).
- Over the past year, APP is up 49.3% and TEM is down 28.6% - APP leads by 77.9 points.
- TEM has been more active in the news (33 items in the past 4 weeks vs 21 for APP).
- Both have 25 recent analyst ratings on file.
PerformanceAPP+49.27%TEM-28.59%
2025-06-09+0.00%2026-06-08
- Company
- Applovin Corporation
- Tempus AI Inc.
- Price
- $572.41+2.75%
- $47.84+3.16%
- Market cap
- $187.19B
- $8.34B
- 1M return
- +14.82%
- -3.23%
- 1Y return
- +49.27%
- -28.59%
- Industry
- Computer Software: Programming Data Processing
- Computer Software: Programming Data Processing
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2024
- News (4w)
- 21
- 33
- Recent ratings
- 25
- 25
APP
Applovin Corporation
AppLovin Corporation engages in building a software-based platform for mobile app developers to enhance the marketing and monetization of their apps worldwide. The company's software solutions include AppDiscovery, a solution to automate, optimize, and manage user acquisition investments for business clients; and MAX, an in-app bidding solution that optimizes purchases of app ad inventory. Its business clients include various advertisers, internet platforms, and others. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Latest APP
- AppLovin to Participate in the 54th Nasdaq & Jefferies Investor Conference
- Director Webb Maynard G Jr was granted 525 shares and sold $1,790,365 worth of shares (3,076 units at $582.04) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 3,157 units (SEC Form 4)
- Director Vivas Eduardo was granted 525 shares, increasing direct ownership by 0.01% to 6,948,997 units (SEC Form 4)
- Director Morgenfeld Todd R was granted 525 shares, increasing direct ownership by 4% to 14,312 units (SEC Form 4)
- Director Messing Barbara was granted 525 shares, increasing direct ownership by 5% to 10,150 units (SEC Form 4)
- Director Georgiadis Mary Margaret Hastings was granted 525 shares, increasing direct ownership by 1% to 36,710 units (SEC Form 4)
- Director Chen Herald Y was granted 525 shares, increasing direct ownership by 0.25% to 207,454 units (SEC Form 4)
- Director Billings Craig Scott was granted 525 shares, increasing direct ownership by 14% to 4,232 units (SEC Form 4)
- Applovin Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 144 filed by Applovin Corporation
Latest TEM
- Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Director Epstein David R sold $12,350 worth of shares (250 units at $49.40) as part of a pre-agreed trading plan, decreasing direct ownership by 0.79% to 31,464 units (SEC Form 4)
- Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
- Wolfe Research resumed coverage on Tempus AI
- Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
- Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
- Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
- Tempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
- CEO and Chairman Lefkofsky Eric P sold $7,763,312 worth of shares (166,250 units at $46.70) as part of a pre-agreed trading plan (SEC Form 4)
- Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology